Screener
Syndax Pharmaceuticals SNDX Business Segments — Collaboration Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:CollaborationLoss.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total Revenue | $64,864 | $20,042 |
| Less: Significant and other segment expenses | ||
| Cost of product sales | 2,633 | 885 |
| Collaboration loss | - | 247 |
| Research and development expenses | ||
| Revumenib-related costs | 25,725 | 20,805 |
| Axatilimab-related costs | 9,633 | 19,711 |
| Other R&D programs | 162 | 921 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — collaboration loss?
- Syndax Pharmaceuticals (SNDX) reported business segments — collaboration loss of $0 in Q1 2026.
- What does business segments — collaboration loss mean?
- This metric captures the financial losses recognized from shared research, development, or commercialization agreements with external partners. It reflects the company's portion of costs or negative outcomes associated with joint ventures in the oncology space. Investors use this to evaluate the financial impact of strategic partnerships on the bottom line.
Ask your AI about Syndax Pharmaceuticals's business segments — collaboration loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude